Clinical Trials Search | Clareo Health

Showing 1-2 of 2 trials

Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLC

NCT07050043

This is a multicenter, two-arm randomized, parallel group design trial to evaluate superiority and safety of low dose Nivolumab (40mg) combined with standard chemotherapy versus standard chemotherapy alone in patients with non-small cell lung cancer.

NSCLC (Non-small Cell Lung Carcinoma)First Line TherapyLocally Advanced/Metastatic NSCLC

Dr Arvindran A/L Alaga123 participantsStarted May 2025

Alor Star, Kedah, Malaysia

TERMINATEDPHASE2

Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer

NCT02257619

The primary objectives of this study is to evaluate the safety and tolerability of itacitinib in combination with docetaxel and to select doses for further evaluation (Part 1, safety run-in portion).

NSCLC (Non-small Cell Lung Carcinoma)

Incyte Corporation9 participantsStarted Sep 2014

Hot Springs, Arizona, United States • Los Angeles, California, United States • Washington D.C., District of Columbia, United States +13 more locations

Data from ClinicalTrials.govTerms

Filters

Filters

Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLC

Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer

Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLC

Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer